CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,311,132 | -28.3% | 60,061 | +4.4% | 0.00% | -100.0% |
| Q2 2023 | $1,828,656 | +41.1% | 57,523 | +8.2% | 0.00% | – |
| Q1 2023 | $1,296,159 | -18.8% | 53,143 | +5.0% | 0.00% | -100.0% |
| Q4 2022 | $1,596,112 | +10.5% | 50,606 | -1.1% | 0.00% | 0.0% |
| Q3 2022 | $1,445,000 | +17.3% | 51,147 | +9.7% | 0.00% | – |
| Q2 2022 | $1,232,000 | +1.3% | 46,616 | +34.2% | 0.00% | – |
| Q1 2022 | $1,216,000 | +126.0% | 34,734 | +109.4% | 0.00% | – |
| Q4 2021 | $538,000 | +13.3% | 16,588 | +2.9% | 0.00% | – |
| Q3 2021 | $475,000 | +195.0% | 16,118 | +156.0% | 0.00% | – |
| Q2 2021 | $161,000 | – | 6,297 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |